Earnings: Tough Times Ahead

Article

Pharmaceutical Executive

Pharmaceutical ExecutivePharmaceutical Executive-03-01-2001
Volume 0
Issue 0

Sodertalje, Sweden-After two consecutive years of robust postmerger growth, AstraZeneca is facing a tough 2001. The company recorded a 16 percent increase in pretax profits for 2000, but CEO Tom McKillop advises that this year}s growth will be in the 5}6 percent range when Losec/Prilosec (omeprazole)-the world}s best-selling medicine-goes off patent and the US launch of its successor Nexium (esomeprazole) is delayed.

Recent Videos
Marcel Botha, 10XBeta
Marcel Botha, 10XBeta
Marcel Botha, 10XBeta
Jennifer Kyle, Condor
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Related Content